PTC Therapeutics, Inc. (PTCT)
PTC Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for rare genetic disorders and other serious conditions. Founded in 1998, the company utilizes innovative drug discovery platforms to develop gene-specific and small molecule treatments aimed at improving patient outcomes. PTC’s portfolio includes therapies for neuromuscular, neurological, and rare genetic diseases.
Company News
PTC Therapeutics' CEO Matthew Klein highlighted the commercial potential of Sephience, a drug for treating phenylketonuria (PKU), projecting significant market opportunities in the U.S. and internationally. The company expects to reach cash flow breakeven with growing sales and believes most patients will respond positively to the treatment.
Novartis reported strong Q2 2025 financial performance with 11% sales growth, double-digit core operating income increase, and raised full-year guidance. Key growth drivers included oncology and specialty medicine brands like Kisqali, Entresto, and Pluvicto.
PTC Therapeutics (PTCT) falls as the EC's advisory committee adopts a negative opinion regarding the renewal of the conditional marketing approval of Translarna to treat nmDMD in the EU.
U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. Shares of The Cooper Companies, Inc. (NYSE: COO) rose sharply during Friday’s session after the company reported better-than-expected first-quarter financial results and raised guidance. Cooper Companies posted adjusted earnings of 85 cents per share, beating mar...